Anne Wojcicki, 23andMe CEO, discusses the complexities of operating a direct-to-consumer genetic testing company. She covers navigating FDA regulations, rebuilding consumer trust post-Theranos, and the ethical dilemmas surrounding data privacy and partnerships. This episode offers critical insights for any DTC enterprise dealing with sensitive consumer data and stringent regulatory environments.
Key takeaways
Understand and proactively address regulatory challenges by engaging with agencies like the FDA, rather than viewing them as adversaries.
Prioritize and transparently communicate data privacy and consent practices to build and maintain consumer trust, especially in sensitive industries.
Learn from industry failures (e.g., Theranos) to anticipate and mitigate risks that could erode public confidence in your entire sector.
Strategically consider partnerships that expand your company's impact and data utility, while carefully navigating ethical implications.
Champion diversity in your data and operations to ensure broad applicability and avoid biased outcomes.
23andMe CEO Anne Wojcicki talks with Recode's Kara Swisher in this live interview recorded at the Rock Health Summit in San Francisco. In this episode: (01:30) Elizabeth Warren's heritage and disputed science; (08:10) 23andMe's business and the FDA under Trump; (12:09) The impact of Theranos' implosion; (14:24) The challenges of the consumer market and health analysis; (18:40) Privacy, consent and safety; (24:57) Techlash and being "lumped in"; (29:59) Anti-aging technology; (32:23) Partnering with GSK, solving cold cases and ethics; (37:40) Insurance companies and what Wojcicki wished she knew at the start; (39:20) Diversity and going public
Learn more about your ad choices. Visit podcastchoices.com/adchoices
